Literature DB >> 16822794

Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model.

Burnett Kelly1, Murad Melhem, Jianhua Zhang, Gerald Kasting, Jinsong Li, Mahesh Krishnamoorthy, Sue Heffelfinger, Steven Rudich, Pankaj Desai, Prabir Roy-Chaudhury.   

Abstract

BACKGROUND: Haemodialysis vascular access dysfunction is currently a huge clinical problem. In an attempt to reduce the morbidity associated with haemodialysis vascular access dysfunction, we have previously developed and validated a local perivascular paclitaxel release system that has been shown to release paclitaxel for at least 3 weeks. The aim of the current study was to evaluate the in vivo use of these perivascular wraps (for both safety and efficacy) at different time points in our pig model of arteriovenous graft stenosis.
METHODS: Paclitaxel-loaded ethylene vinyl acetate wraps were placed around the graft-vein anastomosis on one side, with control polymers being placed on the contralateral side in our pig model of arteriovenous graft stenosis. Animals were sacrificed at early (10-11 days), middle (23-24 days) and late (32-38 days) time points. The entire graft-vein anastomosis was removed at the time of sacrifice and assessed for the extent of luminal stenosis using histomorphometric techniques. RESULT: Graft-vein anastomoses treated with the paclitaxel-loaded polymers had an almost complete absence of luminal stenosis at the middle (23-24 days) and late (32-38 days) time points (when one would expect the development of neointimal hyperplasia) as compared with the contralateral control graft-vein anastomoses (37.90% luminal stenosis in the controls vs 0.10% in the paclitaxel group). There were minimal local side effects from this procedure.
CONCLUSIONS: Our results demonstrate the safety and efficacy of paclitaxel-loaded perivascular wraps in the setting of a pig model of arteriovenous graft stenosis. We believe that such a local approach which could be easily applied at the time of surgery is ideally suited for use in the clinical setting of haemodialysis vascular access dysfunction. It is likely that this novel approach could result in a significant reduction in the huge economic and health morbidity costs currently associated with this recalcitrant clinical problem.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822794     DOI: 10.1093/ndt/gfl250

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  Dialysis Arteriovenous Fistula Failure and Angioplasty: Intimal Hyperplasia and Other Causes of Access Failure.

Authors:  Juan C Duque; Marwan Tabbara; Laisel Martinez; Jose Cardona; Roberto I Vazquez-Padron; Loay H Salman
Journal:  Am J Kidney Dis       Date:  2016-10-27       Impact factor: 8.860

Review 3.  "Venopathy" at work: recasting neointimal hyperplasia in a new light.

Authors:  Alexander S Yevzlin; Micah R Chan; Yolanda T Becker; Prabir Roy-Chaudhury; Timmy Lee; Bryan N Becker
Journal:  Transl Res       Date:  2010-08-13       Impact factor: 7.012

4.  Severe venous neointimal hyperplasia prior to dialysis access surgery.

Authors:  Timmy Lee; Vibha Chauhan; Mahesh Krishnamoorthy; Yang Wang; Lois Arend; Meenakshi J Mistry; Mahmoud El-Khatib; Rupak Banerjee; Rino Munda; Prabir Roy-Chaudhury
Journal:  Nephrol Dial Transplant       Date:  2011-01-10       Impact factor: 5.992

Review 5.  Neointimal hyperplasia associated with synthetic hemodialysis grafts.

Authors:  Li Li; Christi M Terry; Yan-Ting E Shiu; Alfred K Cheung
Journal:  Kidney Int       Date:  2008-07-30       Impact factor: 10.612

6.  Fetuin-A expression in early venous stenosis formation in a porcine model of hemodialysis graft failure.

Authors:  Sanjay Misra; Alex A Fu; Jill L Anderson; James F Glockner; Michael A McKusick; Haraldur Bjarnason; David A Woodrum; Debabrata Mukhopadhyay
Journal:  J Vasc Interv Radiol       Date:  2008-08-09       Impact factor: 3.464

Review 7.  Novel therapies for hemodialysis vascular access dysfunction: myth or reality?

Authors:  Christi M Terry; Laura M Dember
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 8.237

Review 8.  Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis.

Authors:  Timmy Lee; Prabir Roy-Chaudhury
Journal:  Adv Chronic Kidney Dis       Date:  2009-09       Impact factor: 3.620

Review 9.  Local drug delivery to prevent restenosis.

Authors:  Stephen M Seedial; Soumojit Ghosh; R Scott Saunders; Pasithorn A Suwanabol; Xudong Shi; Bo Liu; K Craig Kent
Journal:  J Vasc Surg       Date:  2013-05       Impact factor: 4.268

10.  Cellular phenotypes in human stenotic lesions from haemodialysis vascular access.

Authors:  Prabir Roy-Chaudhury; Yang Wang; Mahesh Krishnamoorthy; Jianhua Zhang; Rupak Banerjee; Rino Munda; Sue Heffelfinger; Lois Arend
Journal:  Nephrol Dial Transplant       Date:  2009-04-17       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.